TNFRSF8 and Hodgkins lymphoma: Several studies have demonstrated the activity of brentuximab vedotin in patients with HL.17,31–36 In a phase I trial SG035-0001 of brentuximab vedotin in 45 patients with CD30 positive hematopoietic cancers (42 of whom had HL) relapsed or refractory after a median of three prior therapies, there were 11 complete remissions (CR), six partial remissions (PR), and 19 cases with stable disease.31 Overall response rate in patients receiving 1.8 mg/kg was 50% and median duration of objective response was 9.7 months with a median progression-free survival of 5.9 months.